Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who currently ...

"Today, many people diagnosed with HR+/HER2- early breast cancer in Europe lack options beyond endocrine therapy to help reduce their risk of cancer coming back. If approved, Kisqali could nearly ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of patients with HR+/HER2- early breast cancer 2 People ...

Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

LaShae Rolle shares her journey of being diagnosed with a rare breast cancer at the age of 26, making her a part of the less ...